Luminate Medical develops a portable medical device that utilizes targeted cooling technology to prevent hair loss during chemotherapy. This device addresses the significant emotional distress caused by hair loss, which is often considered the most traumatic aspect of cancer treatment.
Funding
$22.6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
ABELPHFounders
Product
Problem
Chemotherapy-induced hair loss is a distressing side effect for many cancer patients, leading to emotional distress and impacting their overall quality of life. Current solutions, such as wigs, are often inadequate substitutes and do not prevent hair loss from occurring.
Solution
Luminate Medical is developing Lily, a portable, wearable device designed to prevent hair loss during chemotherapy treatments. The device uses targeted scalp cooling and compression to restrict blood flow to the hair follicles, minimizing their exposure to chemotherapy drugs. By reducing the amount of chemotherapy reaching the scalp, Lily aims to protect hair follicles and significantly reduce hair loss. The non-invasive device is intended to be used during and shortly after each chemotherapy session, offering a convenient and effective solution for patients seeking to maintain their hair during cancer treatment.
Target Audience
The primary target audience includes cancer patients undergoing chemotherapy who are concerned about hair loss, as well as oncologists and healthcare providers seeking to improve the patient experience and reduce the emotional impact of cancer treatment.
Features
- Wearable headset design for convenient use during chemotherapy infusions
- Targeted cooling and compression technology to reduce blood flow to the scalp
- Non-invasive and comfortable for patients during treatment
- Designed to be patient-owned and brought to each treatment session
- Compatible with most solid tumor cancers and various hair types
- Preclinical testing has demonstrated approximately 80% hair retention
- Preclinical testing has demonstrated up to 90% reduction in blood flow around hair follicles